Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.45 |
| ▸ | PPARG | P37231 | 6/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644294 | 0.78 | ALOX15 (0.56) | MEN1KMT2AALOX15CYP19A1MAPK1 | |
| SCHEMBL3513490 | 0.75 | PPARA (0.41) | PPARAPPARGTBXAS1MEN1KMT2A | |
| SCHEMBL814723 | 0.74 | MAOB (0.56) | MEN1KMT2AALOX15CYP19A1MAPK1 | |
| SCHEMBL25218067 | 0.74 | MAOB (0.56) | MEN1KMT2AALOX15CYP19A1MAPK1 | |
| SCHEMBL27874951 | 0.74 | MEN1 (0.34) | MEN1KMT2AALOX15CYP19A1MAPK1 | |
| SCHEMBL4398676 | 0.73 | PPARA (0.51) | PPARAPPARGTBXAS1MEN1KMT2A | |
| SCHEMBL4192083 | 0.71 | PPARA (0.59) | PPARAPPARGTBXAS1KMT2APPARD | |
| SCHEMBL27874950 | 0.70 | HTT (0.34) | MEN1KMT2AALOX15MAPK1KLKB1 | |
| SCHEMBL5333496 | 0.70 | TBXAS1 (0.51) | PPARAPPARGTBXAS1KMT2AALOX15 | |
| SCHEMBL11539611 | 0.69 | SLC22A12 (0.48) | PPARAPPARGTBXAS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046716-B1 | SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF | GENFIT (FR) | 2013-08-14 | — | — | EP | disclosed |
| US-8188148-B2 | Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof | GENFIT (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188148-B2 | Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof | GENFIT (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188148-B2 | Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof | GENFIT (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100286276-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2010-11-11 | — | — | US | disclosed |
| US-20100286276-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2010-11-11 | — | — | US | disclosed |
| US-20100286276-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2010-11-11 | — | — | US | disclosed |
| WO-2007147880-A1 | SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF | GENFIT (FR) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286276-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | DPP3, DPP8, DPP4 | PPARA 11/4885PPARG 56/4885TBXAS1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.